Male
Multidisciplinary Team(s)
Genitourinary Oncology
Department/Research Program(s)
Urology
Cancer Type(s)
Adrenal Cancer
Bladder cancer
Kidney Cancer
Penile Cancer
Prostate Cancer
Testicular Cancer
Ureter Cancer
Contact Info
Email:
cherm@karmanos.org
来自 http://www.karmanos.org/physicians/Michael-Cher?Disease=229PageIndex=1SortDirection=1
Education
Fellowship
National Kidney Foundation Fellow, Urology Laboratory, University of Texas Southwestern Medical School, Dallas, Texas
Fellowship
Clinical and Research Fellow in Urologic oncology and Molecular Cytogenetics, University of California School of Medicine, San Francisco, California
Fellowship
Research Scholar, American Foundation for Urologic Disease, University of California School of Medicine, San Francisco, CA
Medical School
Washington University School of Medicine
Residency
General Surgery and Urology Residency: University of Texas Southwestern Medical Center, Dallas, TX
Professional Memberships/Associations
American Urological Association
Society for Basic Urologic Research
American Association for Cancer Research
Southwest oncology Group
Society of Urologic Oncology
Society of University Urologists
Board Certifications
American Board of Urology
Clinical Interests
Urology Surgeon
Research Interests
Dr. Cher's research interests are focused on the biology of prostate cancer metastasis. His laboratory is actively involved in determining the biological factors responsible for prostate cancer metastasis to bone because bone is the most common location for distant spread of prostate cancer. Using various animal models, his laboratory investigates many of the biological factors involved in human prostate cancer cells interacting with the human bone microenvironment. In collaboration with other researchers at Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, more than 50 papers have been published in this area of research. Many of the findings have become the basis for clinical trials in patients.
Profile
Michael Cher is particularly interested in minimally invasive treatments for prostate cancer, kidney cancer, and bladder cancer. For these cancers, his primary approach is robotic-assisted laparoscopic surgery using the daVinci robotic system. He uses robotic surgery for robotic radical prostatectomy, robotic radical cystectomy, and robotic partial nephrectomy. Robotic surgery provides the surgeon with tremendous visual magnification, a 3-dimensional view, and the ability to perform precise, controlled movements with the robotic surgical instruments. This offers an unparalleled opportunity to operate with precision. The end result is removal of tumors with minimal damage to surrounding tissues. Another area of Dr. Cher's expertise is image-guided treatments. only needles are used to destroy or ablate tumor tissues. For prostate cancer, real-time live imaging with ultrasound is used to place the needles, no surgical incisions are required. One approach is Cryoablation of the Prostate, wher freezing cold temperatures are used to destroy tissues. Cryoablation is appropriate for some patients with newly diagnosed prostate cancer. Cryoablation is also the preferred treatment for recurrent prostate cancer after prior radiation therapy. Another option is focal cryoablation of the prostate, wherin only a portion of the prostate is ablated. Another popular needle-based, minimally invasive image-guided approach is radioactive seed implantation to the prostate, also called brachytherapy. In concert with the Karmanos radiation therapy team, we use tiny needles to place radioactive pellets, or seeds, into the prostate. The subsequent radiation destroys the cancer.
Awards
2006Society of Urologic oncology CapCURE Award for one of three best prostate cancer abstracts at AUA Meeting, Atlanta, GA.
Top Doc, Urology, Hour Magazine
Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year
Publications
PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. In press, Molecular Cancer. Authors: Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML and Chinni SR.
PTEN regulates PDGF ligand switch for -PDGFR signaling in prostate cancer. Am J Pathol. 2012 Mar;180(3):1017-27. doi: 10.1016/j.ajpath.2011.11.021. Epub 2011 Dec 28. Authors: Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR.
Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer. 2011 Nov;2(11):1009-22. doi: 10.1177/1947601912440170. Authors: Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, Dean I, Krass D, Moin K, Bonfil RD, Cher M, Sakr W, Sheng S.
Cediranib inhibits both the intraosseous growth of PDGF D-Positive prostate cancer cells and the associated bone reaction. Prostate. 2012 Sep 1;72(12):1328-38. doi: 10.1002/pros.22481. Epub 2011 Dec 27. Authors: Najy AJ, Jung YS, Won JJ, Conley-Lacomb MK, Saliganan A, Kim CJ, Heath E, Cher ML, Bonfil RD, Kim HR.
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. Oncogene. 2012 Oct 18;31(42):4527-35. doi: 10.1038/onc.2011.573. Epub 2011 Dec 12.PMID: 22158043. Authors: Huang W, Fridman Y, Bonfil RD, Ustach CV, Conley-Lacomb MK, Wiesner C, Saliganan A, Cher ML, Kim HR.
